Stopping GLP-1 Medications: Could It Raise Heart Attack

✓ Medically reviewed | Published: | Evidence level: 1A
A study reported in The BMJ news section suggests that stopping GLP-1 treatment may be associated with a substantially higher risk of heart attack, stroke, or death. Observational findings cannot prove cause and effect, but they add to evidence that these drugs are best treated as long-term therapy, with any discontinuation planned with a clinician.
📅 Published:
✓ Reviewed by iMedic Medical Editorial Team
📄 Cardiovascular Health

Quick Facts

Source
The BMJ news report
Reported signal
Risk possibly doubled after stopping
SELECT trial
About 20% fewer major events

Does stopping a GLP-1 drug raise cardiovascular risk?

Quick answer: A recent study suggests it may, but the evidence is observational and cannot prove that stopping the drug caused the extra events.

According to The BMJ's coverage, a new analysis found that people who stopped GLP-1 receptor agonist treatment had a markedly higher risk of heart attack, stroke, or death than those who continued, with the headline describing a possible doubling of risk. Because the details come from a news summary, the exact figures should be checked against the full publication before being quoted clinically.

Observational designs carry important caveats. People stop these drugs for many reasons, including side effects, cost, supply problems, illness, or a change in health status. Some of those reasons are themselves linked to worse outcomes, a problem known as confounding by indication. Researchers try to adjust for this, but residual bias is hard to remove entirely, so the findings are best read as a warning signal rather than a verdict.

Why might GLP-1 benefits fade after treatment ends?

Quick answer: Weight, blood sugar, and blood pressure improvements tend to reverse after stopping, which could erode the cardiovascular protection.

GLP-1 receptor agonists such as semaglutide reduce appetite, lower blood glucose, and promote weight loss. In the SELECT trial, published in the New England Journal of Medicine in 2023, semaglutide reduced major adverse cardiovascular events by roughly 20 percent in adults with overweight or obesity and established cardiovascular disease but without diabetes. Part of that benefit likely flows from improvements in weight, blood pressure, lipids, and inflammation, although direct effects on blood vessels may also contribute.

Withdrawal studies show these gains are not durable without ongoing therapy. In the STEP 1 extension, participants regained about two-thirds of their lost weight within a year of stopping semaglutide, and cardiometabolic markers drifted back toward baseline. If risk factors return, it is biologically plausible that cardiovascular risk follows, which fits the signal described in the BMJ report.

What should patients do if they want to stop or cannot afford a GLP-1 drug?

Quick answer: Talk to a clinician before stopping, so a plan for monitoring, lifestyle support, and alternative therapies can be put in place.

Patients who plan to stop, or who face cost or supply barriers, should discuss it with their prescriber rather than quietly discontinuing. A clinician can review cardiovascular risk, check blood pressure, lipids, and glucose after stopping, and consider whether other evidence-based therapies should fill the gap. Dose tapering, switching agents, or intermittent strategies are sometimes discussed, though evidence for specific approaches is still limited.

For people with established heart disease or type 2 diabetes, the stakes of discontinuation may be higher than for those using the drugs mainly for weight loss. Structured nutrition support, physical activity including resistance training, and adherence to statins and blood pressure medicines can help maintain risk reduction. Health systems and insurers may also need to consider that interruptions in coverage could carry downstream cardiovascular costs.

Frequently Asked Questions

No. Observational studies show association, not causation. People who stop treatment may differ in health and behavior from those who continue, even after statistical adjustment.

Obesity and type 2 diabetes are chronic conditions, and benefits often fade after stopping. Whether to continue is an individual decision to make with your clinician, weighing benefits, side effects, and cost.

In the STEP 1 extension trial, participants regained roughly two-thirds of their lost weight within about a year of stopping semaglutide.

References

  1. The BMJ. Stopping GLP-1 treatment could double risk of heart attack, stroke, or death, study finds. News report, 2026.
  2. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. 2023.
  3. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022.